EP2698634 - BIOMARKER FOR BREAST CANCER [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 14.09.2018 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 06.10.2017 | ||
Former | Grant of patent is intended Status updated on 22.05.2017 | Most recent event Tooltip | 17.07.2020 | Lapse of the patent in a contracting state New state(s): AL | published on 19.08.2020 [2020/34] | Applicant(s) | For all designated states J-Pharma Co., Ltd. 75-1 Onocho Tsurumi-ku Yokohama-shi Kanagawa 230-0046 / JP | [2014/08] | Inventor(s) | 01 /
ENDOU Hitoshi 1-23-7 Yoshinodai Chuo-Ku Sagamihara-shi Kanagawa 252-0222 / JP | 02 /
OKAYASU Isao 1-31-3-219 Takaidohigashi Suginami-ku Tokyo 168-0072 / JP | [2014/08] | Representative(s) | Osha BWB 2, rue de la Paix 75002 Paris / FR | [N/P] |
Former [2017/45] | Osha Liang 2, rue de la Paix 75002 Paris / FR | ||
Former [2014/08] | Osha Liang SARL 32, avenue de l'Opéra 75002 Paris / FR | Application number, filing date | 12770851.9 | 13.04.2012 | [2017/45] | WO2012JP60114 | Priority number, date | JP20110091378 | 15.04.2011 Original published format: JP 2011091378 | [2014/08] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012141285 | Date: | 18.10.2012 | Language: | JA | [2012/42] | Type: | A1 Application with search report | No.: | EP2698634 | Date: | 19.02.2014 | Language: | EN | [2014/08] | Type: | B1 Patent specification | No.: | EP2698634 | Date: | 08.11.2017 | Language: | EN | [2017/45] | Search report(s) | International search report - published on: | JP | 18.10.2012 | (Supplementary) European search report - dispatched on: | EP | 24.10.2014 | Classification | IPC: | G01N33/574, G01N33/48, G01N33/53, C07K16/28 | [2014/08] | CPC: |
G01N33/57415 (EP,CN,US);
G01N33/574 (KR);
C07K16/28 (EP,KR,US);
G01N33/48 (KR);
G01N33/53 (KR)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/08] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | BIOMARKER FÜR BRUSTKREBS | [2014/08] | English: | BIOMARKER FOR BREAST CANCER | [2014/08] | French: | BIOMARQUEUR POUR LE CANCER DU SEIN | [2014/08] | Entry into regional phase | 15.11.2013 | Translation filed | 15.11.2013 | National basic fee paid | 15.11.2013 | Search fee paid | 15.11.2013 | Designation fee(s) paid | 15.11.2013 | Examination fee paid | Examination procedure | 15.11.2013 | Examination requested [2014/08] | 12.05.2015 | Amendment by applicant (claims and/or description) | 23.05.2017 | Communication of intention to grant the patent | 29.09.2017 | Fee for grant paid | 29.09.2017 | Fee for publishing/printing paid | 29.09.2017 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 23.05.2017 | Opposition(s) | 09.08.2018 | No opposition filed within time limit [2018/42] | Fees paid | Renewal fee | 28.04.2014 | Renewal fee patent year 03 | 27.04.2015 | Renewal fee patent year 04 | 29.03.2016 | Renewal fee patent year 05 | 21.04.2017 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 13.04.2012 | AL | 08.11.2017 | AT | 08.11.2017 | CY | 08.11.2017 | CZ | 08.11.2017 | DK | 08.11.2017 | EE | 08.11.2017 | FI | 08.11.2017 | HR | 08.11.2017 | LT | 08.11.2017 | LV | 08.11.2017 | MC | 08.11.2017 | MK | 08.11.2017 | NL | 08.11.2017 | PL | 08.11.2017 | PT | 08.11.2017 | RO | 08.11.2017 | RS | 08.11.2017 | SE | 08.11.2017 | SI | 08.11.2017 | SK | 08.11.2017 | SM | 08.11.2017 | TR | 08.11.2017 | BG | 08.02.2018 | NO | 08.02.2018 | GR | 09.02.2018 | IS | 08.03.2018 | IE | 13.04.2018 | LU | 13.04.2018 | MT | 13.04.2018 | BE | 30.04.2018 | [2020/34] |
Former [2020/31] | HU | 13.04.2012 | |
AT | 08.11.2017 | ||
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
MK | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
PT | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
TR | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
IE | 13.04.2018 | ||
LU | 13.04.2018 | ||
MT | 13.04.2018 | ||
BE | 30.04.2018 | ||
Former [2020/27] | HU | 13.04.2012 | |
AT | 08.11.2017 | ||
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
PT | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
TR | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
IE | 13.04.2018 | ||
LU | 13.04.2018 | ||
MT | 13.04.2018 | ||
BE | 30.04.2018 | ||
Former [2020/16] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
TR | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
IE | 13.04.2018 | ||
LU | 13.04.2018 | ||
MT | 13.04.2018 | ||
BE | 30.04.2018 | ||
Former [2020/08] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
IE | 13.04.2018 | ||
LU | 13.04.2018 | ||
MT | 13.04.2018 | ||
BE | 30.04.2018 | ||
Former [2019/19] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
IE | 13.04.2018 | ||
LU | 13.04.2018 | ||
BE | 30.04.2018 | ||
Former [2019/12] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
LU | 13.04.2018 | ||
BE | 30.04.2018 | ||
Former [2019/08] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
LU | 13.04.2018 | ||
Former [2018/52] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/40] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/37] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
NL | 08.11.2017 | ||
PL | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/35] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
NL | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SK | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/24] | AT | 08.11.2017 | |
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
NL | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/23] | AT | 08.11.2017 | |
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
NL | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/22] | FI | 08.11.2017 | |
LT | 08.11.2017 | ||
NL | 08.11.2017 | ||
NO | 08.02.2018 | Documents cited: | Search | [XI]EP2146208 (PHARMA CO LTD J [JP]) [X] 1-4 * claim - * * paragraph [0013] - paragraph [0014] * [I] 1-8; | [XY]EP1111048 (JAPAN SCIENCE & TECH CORP [JP]) [X] 1-4 * claim - * [Y] 1-8; | [YD]JP2000342270 (JAPAN SCIENCE & TECH CORP) [YD] 1-8 * claim - * | International search | [X]JP2011024537 (UNIV KINKI, et al); | [X] - SHIN'YA UCHIGASAKI ET AL., "Histopathological and immunohistochemical studies on L-type amino acid transporter 1 (LAT1) expression for breast tumors", JAPANESE JOURNAL OF DIAGNOSTIC PATHOLOGY, (20020731), vol. 19, no. 3, pages 189 - 194, XP008171817 | [Y] - YUKA SASAKI ET AL., "Bunshi Hyoteki Chiryo to Byori Nyugan to Bunshi Hyoteki Chiryo", PATHOLOGY AND CLINICAL MEDICINE, (20060601), vol. 24, no. 6, pages 625 - 633, XP008171811 | [Y] - HARUMI NAKAMURA ET AL., "VIII Byori Saiboshin 3 | Nyugan", MODERN MEDICAL LABORATORY, (20100915), vol. 38, no. 10, pages 1003 - 1008, XP008171810 | by applicant | JP2000157286 | JP2000342270 | JP2001211886 | JP2001046070 | JP2001228146 | JP2001245661 | JPH11511245 | - KANAI, Y. ET AL., J. BIOL. CHEM., (1998), vol. 273, pages 23629 - 23632 | - YANAGIDA 0. ET AL., BIOCHIM. BIOPHYS. ACTA, (2001), vol. 1514, no. 2, pages 291 - 302 | - SEGAWA, H. ET AL., J. BIOL. CHEM., (1999), vol. 274, no. 28, pages 19745 - 19751 | - SAKATA T. ET AL., PATHOL. INT., (2009), vol. 59, pages 7 - 18 | - ODA K. ET AL., CANCER SCI., (2010), vol. 101, pages 173 - 179 | - RAKHA E. A. ET AL., CANCER, (2007), vol. 109, pages 25 - 32 | - LIEDTKE C. ET AL., J. CLIN. ONCOL., (2008), vol. 26, pages 1275 - 1281 | - SASAKI Y. ET AL., BREAST CANCER, (2009), vol. 16, pages 254 - 259 | - IWASE H. ET AL., BREAST CANCER, (2010), vol. 17, pages 118 - 124 | - SINICROPE F. A. ET AL., CANCER RES., (1995), vol. 55, pages 237 - 241 | - Cell engineering Handbook, YODOSHA CO. LTD., (1992), pages 201 - 213 |